Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC1118 in Recurrent Glioblastoma with High EGFR Amplification
NCT03618667Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC1118 in glioblastoma (GBM), sponsored by Samsung Medical Center. Primary endpoint: Progression-free survival at 6 months. Started Jan 2018; status: completed.
02
Drugs
GC1118
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03618667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618667.